1. UKBCG
UK Breast Cancer Group

2. UKBCG aims Membership: 200 UK breast cancer oncologists
Now a major stakeholder in national guidelines
Work with NHS England, NICE, Breast Cancer Now, research groups (NCRI etc), industry
Annual UKBCG meeting (November)
4th year
Clinical/practical lectures and debates
Promotes discussion and collaboration between oncologists

3. Recent stakeholder input to NICE
Title
Status
NICE Guidance - Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer
Response submitted to NICE – NICE confirmed receipt.
NICE guideline on early and locally advanced breast cancer (update)
Consultation due to start on 24 January.
Ribociclib with fulvestrant for treating advanced hormone-receptor positive, HER2-negative breast cancer ID1318
Comments on Draft Scope (by Feb 2018)
Pertuzumab for the adjuvant treatment of HER2-positive breast cancer ID1192
CDA submitted to NICE/Registered as Stakeholder
Committee meeting for this appraisal will be on 22 May 2018 in London.
NICE consultation on changes to the Technology Appraisal programme - phase 2
Further details of the consultation is available via the NICE website
Pembrolizumab for previously treated metastatic triple negative breast cancer ID1246
Comments on draft scope due into NICE by Feb 28th 2018